Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 Combined With Apatinib in Third-line Advanced Gastric Cancer
NCT07371871Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of trifluridine + tipiracil and Rivoceranib in gastric cancer (GC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Objective Response Rate at 12 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilRivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07371871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371871.